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This work is dedicated to people who suffer from tongue cancer. I hope the present research will 
help to improve the management of this malignancy. 
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Abstract  
Oral tongue cancer constitutes the majority of malignancies of the oral cavity. In Finland during 
2013, the age-adjusted incidence rates of oral tongue cancer were 1.7 per 100,000 in males and 0.8 
per 100,000 in females. Staging of the clinical status of tumor size, lymph node, and metastasis 
(cTNM staging) is a widely accepted system for classification of many cancers including oral 
squamous cell carcinoma (OSCC). However, this staging system failed to prognosticate the 
outcome of early stage oral tongue squamous cell carcinoma (OTSCC). Numerous studies designed 
to introduce prognostic parameters and/or models to complement the insufficiency of cTNM staging 
and to predict the patient outcome have been carried out. Many of these prognostic models (or 
systems) were based on histopathologic parameters. However, all of the previously introduced 
models showed little or no predictive power in early stage (cT1-2N0) OTSCC. Thus, the 
identification of markers that predict the outcome of patients with early stage OTSCC is still 
necessary in order to apply effective individualized treatment.  
In this international collaborative study, we have examined the prognostic impact of several 
predictive factors in large patient cohorts from 7 institutions located in 3 geographic regions 
(Finland, Brazil, and USA). Moreover, we have introduced a new simple predictive model (BD 
score) for histopathologic classification and prognostication of early OTSCC. We suggest that this 
model could possibly be easily applied during the surgical resection, so patients with aggressive 
OTSCC could benefit from elective neck dissection (END) during the same procedure. This model 
could offer a step forward toward the personalized management of OTSCC. However, additional 
validation in different patient cohorts is still required.  
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1 Introduction 
The anterior two thirds of the tongue (known as the oral tongue or the mobile tongue) is a subsite 
belonging to the oral cavity, while the posterior third of the tongue (base of the tongue) is a subsite 
of the oropharynx. Squamous cell carcinoma (SCC) arising in the oral tongue (OTSCC) (Fig. 1) is 
reported to have a worse prognosis than SCC arising in the other oral cavity subsites (Rusthoven et 
al. 2008). The reasons for this poorer prognosis of OTSCC are not known. However, some authors 
have attributed it to the dense muscle content of the oral tongue combined with a well-developed 
lymphatic drainage of this part of the oral cavity (Bello, Soini and Salo 2010; Sano and Myers 
2007).      
The clinical staging system (cTNM) is still the cornerstone for risk stratification in oral cancer as 
well as in other cancers (Hubert Low et al. 2015). However, in the early stage of oral cancer 
(especially in early OTSCC), cTNM staging has shown very limited prognostic ability (Piazza et al. 
2014b; Po Wing Yuen et al. 2002). Indeed, the cTNM staging cannot assess the biologic behavior 
of the tumor. This shortcoming of the cTNM staging system may result in inappropriate 
management and may subject the patient to ineffective treatment or unnecessary overtreatment. 
Thus, a patient with an aggressive tumor might receive a surgical approach only, or a patient with a 
non-aggressive tumor might receive a multimodality treatment approach.    
In early stage OTSCC, the management is usually a single-modality treatment consisting of surgical 
resection of the lesion. However, intralesional irradation, also known as brachytherapy, has been 
used successfully to treat early OTSCC (Bourgier et al. 2005; Goineau et al. 2015). 
The high incidence of occult metastases, recurrences and cancer specific mortality among cases 
with early OTSCC make it reasonable to apply multi-modality therapy for such cases in some 
instances. Although hundreds of molecular markers have been suggested over the years as 
prognosticators in oral squamous cell carcinoma (OSCC), only a few have been repeatedly 
validated (Soland and Brusevold 2013). Currently, there are no reliable markers available in clinical 
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practice to select those patients with early OTSCC who might benefit from multi-modality 
treatment. However, the morphological evaluation of the histopathologic features is still the main 
guide for pathologists during the assessment of prognosis of OTSCC specimens. Interestingly, the 
mode and depth of invasion has been shown to be the most important histologic parameter when 
evaluating the prognosis (Bundgaard et al. 2002).  
Since most of the previously published data on prognostic factors of OTSCC (from Finland and 
from other countries) were based on small cohorts of cases, were from a single institution only, 
included SCC cases from all oral cavity subsites, or included early and late stages of cancer in the 
analysis, the current study aimed to evaluate the prognostic value of several predictive parameters 
in a large, international, multi-institution study with a patient cohort including only early stage 
cancers (cT1-2N0) from the anterior two thirds of the tongue (oral tongue or mobile tongue). 
 
Figure 1: Oral tongue squamous cell carcinoma (OTSCC): Early stage (A); and late stage (B). 
This Figure is a kind gift from Professor Tuula Salo. 
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2 Literature review: Oral tongue squamous cell carcinoma 
	  
2.1 Incidence  
Globally, there were 300,400 new cases of oral cavity cancer (including lip cancer) and 145,400 
deaths in 2012 (Torre et al. 2015). Tongue cancer constitutes a high percentage of the oral and 
oropharyngeal cancers. According to the American Cancer Society, 14,320 new cases of tongue 
cancer, and 2,190 deaths due to tongue cancer are projected to occur during 2015 in the USA 
(Siegel, Miller and Jemal 2015). Cancers of the oral tongue and the base of the tongue are usually 
grouped together, so it is sometimes difficult to find the exact number and incidence of OTSCC. 
The Finnish Cancer Society (www.cancerregistry.fi) reported 126 new cases of oral tongue cancer 
in 2013 with 44 deaths as a consequence of the disease.    
OTSCC has been shown to possess unique epidemiologic and biologic characteristics that differ 
from cancers of other subsites of the oral cavity (Rusthoven et al. 2008). In Finland, the incidence 
of oral tongue cancer has increased slightly during last decades, and this increase was slightly 
higher in men (www.cancerregistry.fi). In a recent analysis of the Surveillance, Epidemiology, and 
End Results (SEER), an increase in OTSCC incidence was reported in young white women (Joseph 
et al. 2015). The analysis of national cancer registries in the Nordic countries, however, has shown 
an increase in the incidence of tongue cancer (including base of tongue) in both genders (Annertz et 
al. 2012). Notably, none of the known risk factors (see below) which are implicated in the 
occurrence of oral cancer, appear to provide a clear explanation for the increasing incidence of 
tongue cancer (Annertz et al. 2012).  
2.2 Risk factors  
OTSCC is a multifactorial disease, with use of tobacco (various forms) and alcohol, and areca nut 
(betel quid) chewing being the most significant risk factors for OTSCC as well as for cancers of 
other subsites of the head and neck region (Agnihotri and Gaur 2014; Al-Amad, Awad and Nimri 
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2014; Scully 2011). The reduced risk for OTSCC among never users of tobacco and alcohol was 
documented (Marks et al. 2014). It has been speculated that alcohol consumption is an important 
risk factor in Western populations but not in Asian countries (where tobacco related habits are the 
most important risk factor) (Jayalekshmi et al. 2011). However, other potential risk factors have 
also been reported for the occurrence of OSCC. These factors include: oral potentially malignant 
lesions (e.g. oral lichen planus and oral lichenoid lesions) (Casparis et al. 2015; Sun et al. 2013), 
infection with oncogenic viruses (e.g. human papilloma virus) (Jalouli et al. 2012; Zheng et al. 
2010), dietary factors (Meurman 2010) (e.g. low consumption of vegetables and fruits), poor oral 
hygiene (Oji and Chukwuneke 2012), periodontal disease (Yao et al. 2014), candidiasis (Sanjaya et 
al. 2011), dental trauma (caused by sharp edge of broken tooth or dental prosthesis) (Bektas-Kayhan 
et al. 2014; Manoharan, Nagaraja and Eslick 2014), allergy to dental restorations (Weber et al. 
2012), and genetic susceptibility (Hillbertz et al. 2012). Combinations of such risk factors may 
increase the susceptibility for OSCC development. Of note, a recent review showed that HPV is not 
associated with the recent surge in the incidence of biologically aggressive oral cavity cancer in 
young patients (Salem 2010). 
2.3 Diagnosis   
Early diagnosis of tongue lesions (potentially malignant or malignant) enables the surgeon to limit 
the resected area which diminishes comorbidities. Early diagnosis is also a key to reducing cancer-
specific mortality. The concept of “early” in this context is defined as early in the carcinogenetic 
process, and in the sense of small in size at the time of diagnosis, and with a short time interval 
between the appearance of symptoms and the date of diagnosis (van der Waal et al. 2011). Early 
oral cancers are usually asymptomatic and differ from advanced cancers in terms of clinical 
presentation and outcome (Mashberg and Samit 1995; Seoane et al. 2015). However, a biopsy is 
still the gold standard for the diagnosis of oral cancer, but this approach is limited in screening 
programs to lesions already suspected of malignancy (Brinkmann et al. 2011). Interestingly, cancer-
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related changes of specific salivary biomarkers (e.g. salivary adenosine deaminase) have recently 
been suggested as an effective tool for early diagnosis of tongue cancer (Rai et al. 2011). In 
addition, optical imaging systems and exfoliative cytology (oral brush biopsy) have also been 
suggested to facilitate early diagnosis of oral cancer (Guneri and Epstein 2014). DNA content flow 
cytometry has been shown to be of great value in detecting oral potentially malignant lesions that 
have a high risk for malignant transformation (Giaretti et al. 2013; Ma et al. 2014; Pentenero et al. 
2009). 
For cost-effectiveness, education of the population in self-examination to aid the early diagnosis of 
oral lesions is strongly recommended (Sarode, Sarode and Karmarkar 2012). Although the oral 
tongue has the advantage of being easily accessible for clinical examination, about 40-60 % of 
OTSCC cases are diagnosed at advanced stages (III, IV) (Chen et al. 2008; Ling, Mijiti and 
Moming 2013; Thiagarajan et al. 2014). The delay in diagnosis and management of OTSCC and 
other cancers could be subdivided into primary, secondary and tertiary delays. Primary delay 
(caused by patients themselves) is the duration from the onset of symptoms to seeking medical help 
from a general physician; secondary delay (caused by the general physician) is defined as the 
duration from seeking medical help to referral to the treating hospital (tertiary care center); tertiary 
delay (caused by the treating hospital) indicates the duration from seeking medical advice at a 
tertiary care center to the beginning of the definitive treatment (Joshi et al. 2014). In a Finnish 
study, patient delay was associated with increased comorbidity (Teppo and Alho 2009). It is 
generally recommended that treatment should be carried out within 30 days of diagnosis (Fortin et 
al. 2002).    
According to evidence-based guidelines, during the screening for oral cancer, a practitioner should 
carefully evaluate any signs of potentially malignant or malignant oral lesions especially in people 
at high risk for such lesions (e.g. smokers) (Rai et al. 2011). Patients who present with oral lesions 
(e.g. ulcer, swelling, red or white patch), which last for more than two weeks, should be referred to 
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a specialist (Wolff, Follmann and Nast 2012). Examination should also include clinical inspection 
and palpation of the neck to evaluate the status of cervical lymph nodes. In case of an established 
diagnosis of OTSCC, imaging techniques (ultrasonography, magnetic resonance imaging, computed 
tomography, positron emission tomography) should be used to confirm the presence or absence of 
cervical metastasis. However, it is common that metastases (occult metastases) cannot be detected 
without surgical exploration of neck lymph nodes.  
2.4 Histopathology  
 The WHO grading system (Barnes et al. 2005) classifies OSCCs based on histologic resemblance 
to tissue of origin into well differentiated, moderately differentiated and poorly differentiated 
tumors (Fig. 2) as follows: 
I. Well-differentiated tumor: Tumor tissue (and individual tumor cells) looks similar to 
squamous epithelial cells of the normal oral mucosa. The tumor contains foci of extra- or 
intracellular keratinization. The cells have few mitotic figures and rarely show nuclear 
pleomorphism or variation in cell size and shape. Atypical mitoses are rare or absent. 
II. Moderately-differentiated tumor: Tumor cells are less keratinized and mitotic figures 
are present. There is more nuclear pleomorphism or variation of cell size and shape. A 
few atypical mitotic figures may be seen. 
III.  Poorly-differentiated tumor: Tumor cells are rarely keratinized and they have frequent 
mitotic figures. Nuclear pleomorphism and variation in cell size and shape are 
commonly seen. Atypical mitoses are common. 
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Figure 2: Histopathological appearance of OTSCC. A: Well differentiated tumor; B: Moderately differentiated tumor; 
C: Poorly differentiated tumor. 
 
There are 6 variants of SCC that might occur in the oral cavity, and these were described by WHO 
(Barnes et al. 2005) as follows: 
Verrucous carcinoma: composed of well differentiated squamous cell carcinoma with marked 
keratinization and rare mitoses. Verrucous carcinoma has a pushing border; and lymphocytic host 
response is commonly seen.  
Basaloid SCC: consists of two components, basaloid cells and squamous cells. Basaloid cells have 
hyperchromatic nuclei without nucleoli. Basaloid SCC is characterized by small cystic spaces that 
contain PAS- and Alcian blue-positive material.  
Spindle cell carcinomas: consist of a squamous cell carcinoma component and a spindle cell 
component. The latter forms the bulk of the tumor. The squamous component might present as in-
situ carcinoma or as invasive carcinoma. 
Papillary squamous cell carcinoma: characterized by a papillary growth pattern. Keratosis is 
minimal, and there are foci of necrosis. Papillary SCC invades the stroma as single or multiple nests 
of tumor cells, and there is dense lymphoplasmacytic inflammation at the tumor stroma interface. 
Acantholytic squamous cell carcinoma: characterized by the presence of foci of acantholysis in 
tumor nests, which create a false appearance of glandular differentiation. 
Adenosquamous carcinoma: consists of two components, SCC (in-situ or invasive SCC) and 
adenocarcinoma (tubular structures) with mucin production. 
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2.5 Management   
An interdisciplinary cancer team should determine the management of oral cancer patients on a 
case-by-case basis (Wolff, Follmann and Nast 2012). At early stages of HNSCC, cases are usually 
treated using a single treatment modality (i.e. surgery or radiotherapy) (Langendijk et al. 2010). In 
general, the basic management of OSCC is surgical resection with the exception of very large 
tumors. However, a multimodality treatment (surgical resection, elective neck dissection, 
radiotherapy, and/or chemotherapy) may be required in some cases. For example, in OTSCC cases 
with an aggressive growth pattern or locoregional spread and in advanced cases it is recommended 
to combine surgery and other modalities (e.g. irradiation and neck dissection) (Makitie et al. 2007). 
However, due to the high incidence of occult metastases (23-40%) in early OTSCC (cT1-2N0M0), 
presently there is no agreement on the optimal treatment. Therefore, elective neck dissection (END) 
has been suggested as a routine prophylactic management for early stage OTSCC patients with 
clinically negative nodes (cN0) (Huang et al. 2008). However, in retrospective studies close follow-
up and elective neck dissection have given similar results (D'Cruz et al. 2009; Kelner et al. 2014) as 
was the case in a prospective study as well (Yuen et al. 2009). Although END is associated with 
morbidity, the policy of observation is not always safe. A delayed diagnosis of nodal metastases 
may lead to an increase in the risk of extra-capsular spread and involvement of a larger number of 
nodes by the time of surgery (Kelner et al. 2014). A recent report on early OTSCC has 
recommended a watchful waiting policy only for T1 cases cooperative for close follow-up, while 
END should be considered in T2 cases (Tsang et al. 2011). The sentinel lymph node technique has 
been advocated as an alternative to END in management of early OSCC (Flach et al. 2014; 
Pedersen et al. 2015) and early OTSCC (Fan et al. 2014).  
Postoperative radiotherapy is advised for OTSCC cases with an advanced T stage (T3, T4), positive 
surgical margins, perineural invasion (PNI), positive lymph nodes, or extracapsular spread (ECS) 
(Shim et al. 2010). In early OTSCC, cases with recurrence might benefit from postoperative 
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radiotherapy (Gontarz et al. 2014). A recent study has shown that postoperative brachytherapy is 
associated with better control and a higher rate of survival compared to surgery alone (Goineau et 
al. 2015). However, postoperative treatment should be discussed in an interdisciplinary meeting 
(Wolff, Follmann and Nast 2012). 
2.6 Prognosis  
For HNSCC, the survival rates vary from one center to another. The five-year survival rates 
continue to be around 50-65% of cases according to SEER (Pulte and Brenner 2010; Roh et al. 
2015). Of note, OTSCC is an aggressive HNSCC, and reported to have a poor prognosis compared 
with SCC of other subsites of the oral cavity (Rusthoven et al. 2008). For clinically early stage 
(cT1-2N0) OTSCC, the prognosis is unpredictable with a potential of aggressive invasion, regional 
metastases and cancer mortality. The presence of metastasis is a sign of a grave prognosis in 
OTSCC as well as in many other tumors. However, early OTSCC could be considered as a distinct 
tumor entity with regard to metastases due to the high rate of occult nodal metastases in clinically 
negative nodes. 
2.7 Prevention 
About three quarters of oral cavity cancers could be prevented by interfering with exposure to the 
main risk factors such as alcohol intake and the use of tobacco products (Mangalath et al. 2014; 
Scully 2011). It is not known exactly how much time is required following cessation of these habits 
before the risk of oral cancer is decreased to the level of the never-exposed population. However, 
the risk of head and neck squamous cell cancer (HNSCC) has been reported to decrease in persons 
who have stopped smoking 1-4 years before (Marron et al. 2010). Importantly, recent reports have 
shown that HNSCCs occurring in never drinkers and never smokers commonly arise in the subsite 
of the oral tongue (i.e. OTSCC) (Dahlstrom et al. 2008), and such cases could not be prevented 
before the recognition of predisposing factors.  
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2.8 Prognostic factors for OTSCC 
2.8.1 Demographic prognostic factors for OTSCC 
Age at diagnosis  
Young patients with tongue SCC have a worse prognosis than old patients in some reports recently 
(Hilly et al. 2013; Park et al. 2010). The main weakness of such studies was the small number of 
young patients and/or small number of events (recurrence, and/or deaths from cancer) in young 
patients. However, the effect of age on the prognosis of tongue cancer remains somewhat 
controversial due to inconsistent findings (Hilly et al. 2013; Knopf et al. 2015).  
Many authors have reported an aggressive OSCC in pediatric patients (≤ 20 years) (Ribeiro et al. 
2011; Sidell et al. 2009; Stolk-Liefferink et al. 2008). However, equivalent survival for pediatric 
and older patients with OSCC was reported by Morris et al. (Morris and Ganly 2010). Moreover, in 
another report by Morris and colleagues (Morris et al. 2010), a comparison between a series of 10 
patients with OTSCC ages 15 to 20 years with a series of 40 adult patients showed the pediatric 
patients to have similar or better survival outcomes when compared with adult patients and the 
authors suggest the same treatment approach for both groups.  
 
Gender 
An increased incidence of OTSCC has been reported in white women (especially at a young age) 
(Patel et al. 2011; Saba et al. 2011). However, the reasons for this trend are unclear, although the 
increase of smoking among women may be one explanation (Saba et al. 2011). In oral cancer, 
however, gender was not widely recognized as a significant prognostic factor (Girod et al. 2009). 
Only a few reports in the literature have elaborated on the role of gender in the prognosis of all 
stages of OTSCC. Similar survival rates in men and women have been reported by Garavello et al. 
(Garavello et al. 2008), but an aggressive behavior with a worse prognosis in young women was 
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reported by	  Vargas et al. (Vargas et al. 2000). Interestingly, Benowitz et al. (Benowitz et al. 2006) 
reported that women have a faster metabolism of nicotine than men; and a similar amount of 
smoking was reported to cause more oral cancer in women than in men (Zavras et al. 2001).  
 
Socioeconomic status  
Socioeconomic status has been reported to correlate with survival of oral cancer patients. One 
explanation may be the occurrence of more comorbidities in oral cancer cases in low socioeconomic 
groups (Lee et al. 2012). On the other hand, patients with a high socioeconomic status have more 
opportunities to improve their health status by financial means, knowledge and social connections 
(Lee et al. 2012). Notably, a limited access to medical services affects the outcome of patients. As 
an example, a study from the University of Pittsburgh Medical Center (USA) showed that uninsured 
HNSCC patients were at an advanced stage of cancer at the time of diagnosis, and subsequently at 
high risk of death compared with patients who had private insurance (Kwok et al. 2010). In 
contrast, the availability of medical services could improve the survival. As an interesting example, 
regular visits to a dental clinic were reported to aid in the diagnosis of oral cancer at an earlier stage 
(Langevin et al. 2012), which subsequently could improve the prognosis. Although information on 
the effect of socioeconomic status on the prognosis of OTSCC is lacking, Yang et al. (Yang et al. 
2010) reported that higher socioeconomic status was strongly associated with higher quality of life 
for tongue cancer patients after surgery. Such improvement in quality of life would improve the 
survival rates.  
 
Tobacco use, betel quid chewing and alcohol consumption 
Tobacco use and alcohol consumption have been reported as adverse prognostic factors in OSCC 
(Girod et al. 2009; Jerjes et al. 2012). A recent study from Brazil has shown an impact on the 
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prognosis of OTSCC for smoking but not for alcohol consumption (Rodrigues et al. 2014). OTSCC 
in non-smokers and non-drinkers has been speculated to represent a special entity with aggressive 
behavior and poor prognosis (Sebastian et al. 2014), but, the debate is still ongoing due to 
conflicting findings. A study by Bachar et al. (Bachar et al. 2011) reported similar outcomes of 
OTSCC cases with or without risk factors, but their analysis of a subgroup of young patients (less 
than 40 years) showed a poor prognosis in young patients without risk factors. Moreover, Durr et al. 
(Durr et al. 2013) reported decreased survival of OTSCC patients who were never-smokers, but the 
survival difference was not statistically significant. 
 
Obesity  
The effect of increased weight on the prognosis of cancers has been reported previously (Calle et al. 
2003). Notably, a recent study found a significant association between obesity and poor survival 
(both DSS and DFS) in early stage OTSCC (Iyengar et al. 2014). Although there is no specific 
explanation of how obesity contributes to progression and prognosis of OTSCC, some 
recommended interventions include exercise, reduction of weight and the use of anti-inflammatory 
drugs (Iyengar et al. 2014). However, more evidence is required before obese patients with early 
OTSCC can be considered at high risk of poor prognosis with a need for more aggressive treatment.  
 
2.8.2 Clinical prognostic factors for OTSCC   
Clinical staging (cTNM)   
cTNM staging is based on the measurement of tumor diameter (T), lymph node status (N) and 
distant metastases (M). Worldwide, it is still the cornerstone of clinical staging during risk 
stratification and treatment planning of oral carcinomas. However, cTNM staging does not assess 
the biological behavior of the tumor. In addition, the cTNM system shows a low or no prognostic 
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ability in early OTSCC (Po Wing Yuen et al. 2002; Yanamoto et al. 2013). Many recent reports 
suggested improving it by the incorporation of other parameters that were reported as good 
predictors for OTSCC. Of these suggested parameters, the depth of invasion or tumor thickness has 
been widely reported for this purpose (Piazza et al. 2014a).  
 
Clinical appearance of the tumor  
There is very little information on the impact of the clinical appearance of the tumor on the 
prognosis of OTSCC. However, an endophytic  appearance of OTSCC at the time of presentation is 
associated with a poorer prognosis compared to cases with an exophytic (proliferative) appearance 
(Sharma et al. 2013). In addition, the presence of oral lichen planus (currently or previously) was 
also reported as a sign of poor prognosis in early OTSCC (Bonnardot et al. 2011). Other factors 
related to clinical appearance such as a more posteriorly located OTSCC (i.e. tumors located in the 
posterior part of the oral tongue) confer an adverse prognosis (Bonnardot et al. 2011). It might be 
speculated that some of these posteriorly located cancers could have arisen at the base of the tongue 
(where the epithelium originated from the endoderm and where HPV is highly implicated in 
carcinogenesis), but it has been recognized clinically as carcinoma of the oral tongue (where the 
epithelium originated from the ectoderm and factors other than HPV were involved). However, 
such speculation is not supported by evidence. 
 
Midline involvement  
Extension of the primary tumor to the midline is an adverse prognostic feature in OTSCC, and it 
predicts the pattern of LN metastasis (Lloyd et al. 2012; Mallet et al. 2009). A similar finding was 
also reported in cohorts of OSCC (Capote-Moreno et al. 2010; Kowalski et al. 1999). Importantly, 
in OTSCC, contralateral LN metastasis (considered as a sign of a very poor prognosis) occurs if the 
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cancer involves the tongue midline (clinically or subclinically) or if the cancer is located close to 
the midline where small lymphatic vessels may cross to the other side (Lloyd et al. 2012).  
 
Recurrence 
The return of cancer after treatment is defined as recurrence, although the length of time to consider 
the lesion as recurrence (but not a second primary) is not well defined. The presence of recurrent 
disease (local, regional or both) is the most common cause of treatment failure and has been 
documented to imply poor prognosis in OTSCC (Peng et al. 2014; Yanamoto et al. 2013). The 
cause of cancer recurrence is usually attributed to incomplete surgical resection of the tumor. 
However, in early OTSCC, which is characterized by the small size of the lesion and easy surgical 
access, other causes such as aggressive behavior of the tumor may also be considered. 
 
Second primary tumor  
A second malignancy that presents in a certain tract simultaneously (i.e. synchronously) or after (i.e. 
metachronously) the diagnosis of an index tumor is known as a second primary tumor (van der 
Waal and de Bree 2010). Both the primary tumor and the second primary must be malignant, must 
be distinct, and the probability of metastasis must be excluded (i.e. the second primary is not a 
metastasis from the primary tumor) (Warren and Gates 1932). Although the latter two criteria are 
challenging, analysis of genetic background would, indeed, fulfill such criteria. Patients with oral 
cancer have an estimated risk of 10-35% for occurrence of second primary malignancy in the upper 
aerodigestive tract (van Oijen and Slootweg 2000). However, the risk varies among the age groups, 
with young patients having the highest risk (Bosetti et al. 2011). In tongue cancer, 9% of cases were 
reported with a second primary tumor (Li et al. 2011). Most of the second primary malignancies in 
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early OTSCC patients occur in the oral cavity and the oropharynx; and the rate of second primary 
malignancies was associated with smoking and alcohol consumption (Koo et al. 2015).  
The concept of field cancerization indicating foci of invisible genetic alterations in tissues 
surrounding an OSCC (or in oral precancerous fields) has been described in oral cancer patients 
(Angadi et al. 2012; Bremmer et al. 2008). These field alterations could be considered as a cancer 
risk factor (Jaiswal et al. 2013). Based on this concept, it could be speculated that the surgeon has 
performed a successful surgical resection of early OTSCC with safe margins, but the treatment 
failure may depend on genetic alterations in the surrounding tissues due to long term exposure to 
carcinogens. Therefore, the identification of genotypically abnormal cells at histologically clear 
margins could be useful in prediction of cases at high risk of local failure (Jaiswal et al. 2013). 
 
Metastasis (Nodal or Distant)  
Metastasis is a complex process in which cancer cells from the primary tumor disseminate to other 
organs. The biochemical determinants of OTSCC metastasis are not well understood (Sano and 
Myers 2007). During the diagnosis of OTSCC (irrespective of tumor size), the presence of positive 
lymph nodes in the neck (cN+) is a sign of poor prognosis, and indicates a need for intensive 
treatment of the neck including END and/or radiotherapy. However, in clinically and 
radiographically negative lymph nodes (cN0), almost one third of the patients were reported to have 
occult nodal metastasis on histopathological examination of dissected nodes (Thiagarajan et al. 
2014), and the corresponding percentage is higher in stage II. As an example, An and co-
investigators (An et al. 2008) reported occult nodal metastasis in 15.4% of stage I cases, and 42.9% 
in stage II. The presence of occult metastasis is recognized as an independent predictor of poor 
survival in early OTSCC (Ganly, Patel and Shah 2012). 
Notably, the navigation of neck lymph nodes through sentinel lymph node biopsy has shown a 
predictive power superior to END for the prognostication of LN metastasis in early OTSCC (Fan et 
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al. 2014). The use of this novel surgical approach has been widely suggested recently (Fan et al. 
2014; Pedersen et al. 2015). The published studies have shown excellent intraoperative assessment 
of cervical LNs (Yamauchi et al. 2015). However, arguments against this approach have been raised 
including the time consuming and labor-intensive process in the pathology laboratory (Liu et al. 
2011).  Thus, it might be still necessary to use traditional prognostic markers that could help select 
the patients who would benefit from this navigation surgery. Interestingly, indocyanine green 
fluorescence has been used recently to guide the sentinel node biopsy, which has improved this 
technique (Nakamura et al. 2015; van den Berg et al. 2012). 
In advanced stages of OTSCC, distant metastases are reported to occur in about 6% of cases 
(Thiagarajan et al. 2014). Metastasis of OTSCC to distant sites is a sign of very poor prognosis 
(Goodman et al. 2009); and the most affected sites are the lungs and the bones (Sano and Myers 
2007).  
 
Comorbidity  
Comorbidity is defined as the presence of other medical conditions (e.g. hepatic, respiratory, 
cardiovascular, gastrointestinal, or renal diseases) in addition to the primary tumor (but not caused 
by the latter) (Datema et al. 2010). Comorbidities have been reported as indicators of a worse 
prognosis in patients with OTSCC (Okuyemi, Piccirillo and Spitznagel 2014) and HNSCC in 
general (Datema et al. 2010). 
 
2.8.3 Histopathologic prognostic factors for OTSCC  
The daily practice of a pathologist includes the evaluation of many histopathologic prognostic 
features to assign proper histological stratification to guide the clinician towards a suitable 
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treatment modality (i.e. to avoid undertreatment or overtreatment). Importantly, researchers have a 
keen interest in cancer cells at the invasive front (IF), and the IF area is usually evaluated by 
pathologists because these cells have aggressive behavior that differs from that of cells in other 
parts of the tumor (Bronsert et al. 2014; Bryne et al. 1992; Christofori 2006; Jensen et al. 2015a).  
In addition, critical biological events such as epithelial mesenchymal transition (EMT) are 
speculated to occur at the IF (Jensen et al. 2015a; Liang 2011).  
 
Histopathologic grading systems   
Histopathologic grading systems were introduced many decades ago for the classification and 
prognostication of oral cancers. Such models have been proposed by Broders (Broders 1920; 
Broders 1941), Jakobsson et al. (Jakobsson et al. 1973), Anneroth et al. (Anneroth, Batsakis and 
Luna 1987), Bryne et al. (Bryne et al. 1992; Bryne et al. 1989), and most recently by Brandwein-
Gensler et al. (Brandwein-Gensler et al. 2005). Since their introduction, numerous reports by other 
researchers have addressed the predictive ability of such grading systems in OSCC. However, none 
of these models have shown prognostic power in early stage OTSCC. 
 
A. Tumor grade  
The first quantitative grading system was introduced by Broders (Broders 1920), and this grading 
has been widely used for the histopathologic staging of SCC in many locations. Based on the degree 
of tumor cell differentiation (Fig. 2), Broders divided SCCs into 3 grades: Low grade (Well-
differentiated tumor), intermediate grade (Moderately-differentiated tumor) and high grade (Poorly-
differentiated tumor) tumors. This system is explained in more detail in section 2.4. 
According to this system, high-grade tumors have been suggested to behave aggressively and have 
a poor prognosis. This grading system might be criticized as it does not evaluate the tumor-host 
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interface, but it is still widely included in pathology reports of OSCC. However, there are reports 
that have shown a prognostic power of this system in OSCC (Thomas, Stedman and Davies 2014), 
while others have reported a weak predictive ability in early OTSCC (Ganly et al. 2013). 
 
B. Grading of Malignancy 
In 1973, Jakobsson and colleagues (Jakobsson et al. 1973) introduced a system for grading of 
malignancy that was applied first in a patient cohort with laryngeal cancer and later was applied to 
OSCC. Jakobsson´s system is based on evaluation of the following parameters: tumor structure, 
degree of keratinization, nuclear pleomorphism, mitoses, mode of invasion, stage of invasion, 
vascular invasion and cellular response (Table 1).  
Table 1: Histopathologic parameters and their scoring in the Jakobsson grading system (1973).  
 
Morphologic characteristics 
 
Points  
 1 2 3 4 
 
Grading of tumor cell population  
 
Structure Papillary  Strands Small cords and 
groups of cells 
Marked 
dissociation of cells 
Differentiation Highly keratinized Moderately 
keratinized 
Poorly keratinized No keratinization 
Nuclear pleomorphism Few enlarged 
nuclei (EN) 
Moderate number 
of EN 
Numerous irregular 
EN 
Anaplastic 
immature EN 
Mitoses Single Moderate number Great number Numerous 
 
Grading of tumor host relationship 
 
Mode of invasion Well marked 
borderline 
Cords (less marked 
borderline) 
No distinct 
borderline 
Diffuse growth 
Stage of invasion Possibly Microcarcinoma Nodular into 
connective tissue 
Massive 
Vascular invasion None Possibly Few Numerous 
Lymphoplasmacytic 
infiltration (cellular 
response) 
Marked Moderate Slight None 
Risk stratification:  
Low risk: < 15 points; Intermediate risk: 15-20 points; High risk: > 20 points.  
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C. Multifactorial grading system  
In 1987, Anneroth et al. (Anneroth, Batsakis and Luna 1987) reviewed the literature and 
recommended a new system of malignancy grading in oral squamous cell carcinomas (Table 2) 
based on the evaluation of parameters related to both tumor cell population (degree of 
keratinization, nuclear pleomorphism, number of mitoses) and tumor-host relationship (pattern 
of invasion, depth of invasion, inflammatory cell infiltration).   
Table 2: Histopathologic features of the malignancy grading system introduced by Anneroth et al. (1987) 
 
 
Morphologic characteristics 
 
Points  
 1 2 3 4 
 
Grading of tumor cell population 
 
Degree of keratinization > 50% of cells 20-50% of cells 5-20% of cells 0-5% of cells 
Nuclear pleomorphism (NP) Little NP Moderate NP Abundant NP Extreme NP 
Number of mitoses/High 
power field  
 
0-1 2-3 4-5 > 5 
 
Grading of tumor host relationship 
 
Pattern of invasion (POI) Pushing borders Infiltrating, solid 
cords, bands and/or 
strands 
Small groups or 
cords of infiltrating 
cells 
Marked cellular 
dissociation in 
small groups and/or 
in single cells 
Stage of invasion 
(Depth) 
Carcinoma-in-situ Distinct invasion 
involving lamina 
propria only 
Invasion below 
lamina propria 
adjacent to muscles 
and salivary gland 
tissues 
Extensive and deep 
invasion 
 
Lymphoplasmacytic 
infiltration 
Marked Moderate Slight None 
Malignancy grading: Grade I: 6-12 points; grade II: 13-18 points; grade III: 19-24 points. Higher grade is proposed to 
have poorer prognosis.  
 
D. Malignancy grading system according to invasive front   
Bryne and colleagues (Bryne et al. 1989; Bryne, Thrane and Dabelsteen 1991) suggested that 
cellular differentiation of the upper part of the tumor does not have any prognostic value in OSCC, 
while the invasive cells (i.e. cancer cells at the IF) of the same specimen have a significant 
prognostic value. So they proposed a grading system based on the following 5 parameters: degree of 
keratinization, nuclear pleomorphism, number of mitoses, pattern of invasion and inflammatory cell 
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infiltration. At the invasive front of the OSCC, they (Bryne et al. 1992) evaluated the same 
parameters used previously by Anneroth et al. (Anneroth, Batsakis and Luna 1987). Interestingly, 
they eliminated the stage of invasion; and also suggested omitting the number of mitoses as the 
latter is a time-consuming parameter affecting the reproducibility of the malignancy grading (Bryne 
et al. 1992). According to this system, malignancy grading ranged from 4 to 16 points divided into 
grade I (4-8 points), grade II (9-12 points), and grade III (13-16 points). A higher grade predicted a 
poorer prognosis. 
 
E. Histologic risk assessment model 
Brandwein-Gensler et al. (Brandwein-Gensler et al. 2005) proposed the histologic risk score (HRS) 
model based on evaluation of three parameters: worst pattern of invasion (WPOI), lymphocytic host 
response (LHR), and perineural invasion (PNI) (Table 3).  
Table 3: HRS of Brandwein-Gensler et al. (2005)  
Parameter Type Definition score assigned 
Worst 
pattern of 
invasion 
(WPOI) 
Type 1 Pushing border 0 
Type 2 Finger-like growth 0 
Type 3 Large tumor islands (> 15 cancer cells) 0 
Type 4 Small tumor islands (≤ 15 cancer cells) 1 
Type 5 Tumor satellites which lie 1 mm or more away from the main 
tumor mass or the nearest satellite (under x 20 magnification) 
3 
Lymphocytic 
host response 
(LHR) 
Type 1 Strong 0 
Type 2 Intermediate 1 
Type 3 Weak 3 
Perineural 
invasion 
(PNI) 
 
None No PNI 0 
Small Tumor wrapping around small nerve (< 1 mm in diameter) 1 
Large Tumor wrapping around large nerve (≥ 1 mm in diameter) 3 
Risk stratification:  
Low risk: score 0; intermediate risk: score 1 or 2; and high risk: score 3 or higher. 
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Margin status 
Close margins (<5 mm) are widely used as a predictor of worse prognosis and subsequently an 
indication for adjuvant therapy in OSCC (Ch'ng et al. 2013). In early stage OTSCC, the margin 
status of a glossectomy specimen was reported to be a predictor of local control (Chang et al. 2013). 
However, wide surgical margins in all directions (lateral, medial, anterior, posterior, mucosal and 
deep) have been recommended in early OTSCC (Iseli et al. 2012). The use of margin status as a 
prognostic marker is still an issue of debate due to factors related to the method of specimen 
processing, variations in the amount of shrinkage of the specimens and the use of different cutoff 
points for defining adequate margins (El-Fol et al. 2015; Mistry, Qureshi and Kumaran 2005). Such 
factors should not be neglected. In addition, the lack of compartmentalized anatomy in the tongue 
causes difficulties in the assessment of margin status of OTSCC (Montero et al. 2014). It has also 
been reported that surgery alone (without any postoperative adjuvant treatment) will provide 
acceptable control in OSCC cases where close (but uninvolved) surgical margins were the only 
adverse feature (Ch'ng et al. 2013). However, in clinical practice most of the cases with positive 
margins are stratified as high-risk cases and are eligible for postoperative chemo-radiotherapy, 
irrespective of the adequacy of such margins (Montero et al. 2014).  
 
Dysplasia at margins  
In oral leukoplakia, the presence of epithelial dysplasia has been recognized as a risk for poor 
prognosis (i.e. malignant transformation) (Weijers et al. 2002). Similarly, the presence of moderate 
or severe dysplasia at the resection margins of early OTSCC has been recognized as an adverse 
prognostic feature (Sharma et al. 2013; Sopka et al. 2013). From a surgical point of view, further 
excision of such dysplastic tissues should be performed in the same operation, and may reduce the 
risk of local recurrence.  
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Perineural invasion (PNI)   
The invasion of cancer cells around and/or into a nerve has been reported as an adverse predictive 
factor in OTSCC (Goodman et al. 2009; Shen et al. 2014; Tai et al. 2012), and it is one of the 
parameters often included in pathology reports of many cancers. In addition, PNI has been one of 
the parameters in a proposed histologic staging model of early OSCC (Li et al. 2013). Surprisingly, 
a recent study on early OSCC (cT1-2N0) reported that PNI correlated significantly with neck 
recurrence and with a worse survival in T1 (n=146), but not in T2 (n=161) cases (Tai et al. 2013). 
The mechanism of perineural growth in oral cancer is still unclear. In early stage OTSCC, 
Kolokythas and colleagues (Kolokythas et al. 2010) suggested that both nerve growth factor (NGF) 
and its high-affinity receptor tyrosine kinase A (TrkA) participate in the mechanism of PNI. In 
addition, it was postulated that tumor cells interact with the microenvironment of the nerve, and that 
tumor cells in this new environment behave differently, and subsequently more aggressively (Roh et 
al. 2015). However, the difficulties in evaluation of PNI require improvements in the method of 
examination (e.g. use of nerve-specific staining) (Marchesi et al. 2010). 
 
Lymphovascular invasion (LVI) 
Lymphovascular invasion (LVI) is defined as the presence of cancer cells in the wall or in the 
lumen of lymphatic or blood vessels (Jardim et al. 2015). It has been documented as a useful 
prognosticator in OTSCC (Michikawa et al. 2012; Okuyemi, Piccirillo and Spitznagel 2014). Such 
an invasion of cancer cells into these vessels provides an avenue for nodal and distant metastases.  
However, the assessment of LVI is difficult using H-E staining, while it is easy to identify in 
Elastica van Gieson (EVG) staining (Michikawa et al. 2012).  
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Muscle invasion   
The tongue is a muscular organ, and muscle invasion is quite common in OTSCC (Sharma et al. 
2013). Recent studies have reported that invasion of intrinsic muscles has prognostic power for 
recurrence and/or occult lymph node metastasis in OTSCC (An et al. 2008; Chandler et al. 2011; 
Sharma et al. 2013). In cases of cT1N0 OTSCC, An et al (An et al. 2008) recommend performing 
END when involvement of tongue muscles is present. 
 
Pattern of invasion 
In many cancers (including early OTSCC), the pattern of tumor invasion (POI) has been shown to 
be a predictive histopathologic feature (Aita et al. 2015; Horn et al. 2012; Li et al. 2013; Soland et 
al. 2008; Yanamoto et al. 2013). The POI (Fig. 3) has been described as a “cohesive” POI (in which 
the tumor invades as large pushing borders or as finger-like growths) or as an “infiltrative” POI (in 
which the tumor invades as small islands or strands of ≤ 15 cancer cells). Recently, Brandwein-
Gensler and colleagues (Brandwein-Gensler et al. 2005) have described tumor satellites as a part of 
an infiltrative POI. A tumor satellite is defined as the presence of isolated tumor islands 1 mm or 
more away from the main tumor mass or from the closest other tumor satellites. Tumor satellites are 
reported to be a predictive feature of occult metastasis in early OTSCC (Yang et al. 2011). In a 
further development, Chang et al. (Chang et al. 2010) have introduced the invasive pattern grading 
score (IPGS) as a modification of POI in OSCC. 
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Figure 3: Large tumor islands as an example of cohesive POI (A); and small tumor islands as 
an example of infiltrative POI (B). 
 
 
Tumor budding (TB)  
The presence of single cancer cells or small clusters of less than five cells at the IF (Fig. 4) is 
defined as tumor budding (TB), and it has been widely recognized as a prognostic feature in many 
cancers including tongue cancer (Karamitopoulou 2013; van Wyk et al. 2014; Wang et al. 2011). 
According to Mitrovic et al. (Mitrovic et al. 2012), tumor budding (sprouting) was first described 
by Imai in the 1950s. Later on, numerous studies have evaluated TB in different cancers. The 
biological background of TB is still not fully understood. However, many researchers have found a 
strong correlation between TB and markers related to progression of cancer. For example, TB 
correlated with emergence of CAFs and laminin-5 gamma 2 in OSCC (Marangon Junior et al. 
2014); and TB has also been correlated with other markers in colorectal cancer (Dawson et al. 2014; 
Guzinska-Ustymowicz 2006). In addition, TB correlated with EMT in tongue carcinoma and other 
malignancies (Karamitopoulou 2012; Liang et al. 2013; Wang et al. 2011; Yusra, Semba and 
Yokozaki 2012). EMT is well known as a key player in cancer progression. In OTSCC, it has been 
demonstrated that markers of EMT are common in both primary and metastatic OTSCC (Vered et 
al. 2010). Importantly, a recent study has reported TB as a prognosticator for occult lymph node 
metastasis and poor survival in early tongue cancer (Xie et al. 2014). The intensity of TB at the IF is 
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usually determined by counting of the buds in a high power field using a magnification of ×20 (e.g. 
equal to 1.3 mm square). However, other magnifications and areas were also used.  
 
Figure 4: Intensity of tumor budding at IF of early OTSCC. A and B: Low intensity (< 5 buds); C: 
High intensity (≥ 5 buds).  
 
 
Depth of invasion (DOI) 
The depth of invasion or tumor thickness (these terms are often used as synonyms) has been widely 
recognized as a significant prognosticator in oral cancer. There is wide agreement from numerous 
researchers about the predictive role of DOI in OTSCC. On the other hand, there is disagreement 
about the optimal cutoff for risk stratification in relation to DOI, where cutoff points such as 2mm 
(Ganly, Patel and Shah 2012), 4mm (Ganly et al. 2013; Han et al. 2015), 5mm (P et al. 2003), and 
other DOI values (Huang et al. 2009; Po Wing Yuen et al. 2002) have been suggested. However, a 
recent meta-analysis suggested 4 mm as the optimal cutoff point in OSCC (Huang et al. 2009). The 
accuracy of non-invasive preoperative measurement of DOI by the use of magnetic resonance 
imaging (Iwai et al. 2002; Jung et al. 2009; Okura et al. 2008; Preda et al. 2006) and/or 
ultrasonography (Natori et al. 2008) may increase the importance of this parameter in 
prognostication. Notably, modification of the cTNM staging system by the incorporation of DOI 
has been recommended (Hubert Low et al. 2015; Piazza et al. 2014a).  
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Pathologic lymph node status (pN status)  
The occurrence of occult metastasis in negative (clinically and radiographically) LN of the neck 
ranges between 23-40% (Feng et al. 2014; Peng et al. 2014) in early OTSCC cases. Although the 
pathologic staging of cervical LNs provides valuable prognostication in such cases (Ganly, Patel 
and Shah 2012), it cannot be applied before neck dissection which is associated with morbidity.  
 
Extra-capsular spread (ECS)   
The spread of metastatic tumor cells beyond the capsule of a lymph node is an indicator of more 
aggressive behavior in HNSCC (Puri, Fan and Hanna 2003). In OTSCC, early recurrence and 
subsequent poor prognosis was strongly associated with the presence of ECS (Greenberg et al. 
2003; Okuyemi, Piccirillo and Spitznagel 2014). Similar to pN status, the main argument against 
ECS is that it can be examined only after neck dissection.      
 
2.8.4 Immunohistochemical prognostic indicators in OTSCC  
The advance in molecular pathology research has discovered numerous markers associated with 
cancer progression. Such markers may reveal molecular differences between early stage cancers, 
and subsequently may help in assessing the prognosis. Using immunohistochemical staining of 
formalin-fixed sections, researchers have tested hundreds of molecules to evaluate their prognostic 
ability in oral cancer. Søland et al. (Soland and Brusevold 2013) recently reviewed the literature for 
any immunohistochemical markers introduced as prognosticators of OSCC during the period 
between October 2006 and October 2012. They found a total of 214 immunohistochemical markers 
in 172 prognostic studies of OSCC. They noted that most of these markers (75%) were reported 
only once without later validation, and thus the significance could not be analyzed. Only three 
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frequently used markers could be included in that review: Ki67 (11 studies), p53 (11 studies), and 
the epidermal growth factor receptor (EGFR) (7 studies) (Soland and Brusevold 2013).  
In Table 4, we present a list of immunohistochemical markers tested recently for prognostication of 
OTSCC.  
Table 4: Prognostic immunohistochemical markers for OTSCC evaluated since 2008   
Author 
 
Marker Number 
of cases 
Prognostic role 
(Wangsa et al. 2008) 
	  
Ki-67 76 cases Ki-67 is a predictor of loco-regional recurrence in early 
OTSCC 
 
(Bello et al. 2008) Claudin 7 97 cases Claudin 7 is a predictor of disease-specific survival (DSS) 
in OTSCC 
 
(Hayry et al. 2010) Bmi-1 73 cases Bmi-1 is predictor of recurrence in early OTSCC 
(Zhang et al. 2011) Lymphatic vessel 
density (LVD) 
  
138 cases LVD is a predictor for lymphatic metastasis in OTSCC 
(Mostaan et al. 2011) CD44 92 cases  Underexpression of CD44 is a significant marker for 
cervical lymph node metastasis 
(Wang et al. 2012) Snai2  129 cases Snai2 is an important factor in progression of OTSCC 
(Dayan et al. 2012) CD163+ CD80+ 
Foxp3+ 
64 cases A high score of CD163+ CD80+ Foxp3+ associated with 
poor survival in OTSCC 
(Zhang et al. 2011)  MMP-1 and MMP-
2 
 138 cases Overexpression of MMP-1 and MMP-2 was a risk factor 
for lymph node metastasis in OTSCC 
 
(Makinen et al. 2012; 
Makinen et al. 2014) 
MMP-13 and 
MMP-7  
73 cases MMP-13 and MMP-7 are predictors of poor prognosis in 
cT1-2N0 OTSCC 
 
(Aparna et al. 2014) MMP-2 and MMP-
9 
59 cases MMP-2 and MMP-9 have strong predictive value for local 
recurrence, regional metastases, distant metastasis and 
shorter survival in early OTSCC 
 
(Bitu et al. 2013) Cathepsin K 121 cases Cathepsin K has a protective role in the progression of 
OTSCC and predicts the survival 
 
(Kauppila et al. 2014; 
Kauppila et al. 2013)  
TLR-5 and TLR-9 121 cases TLR-5 and TLR-9 are predictive markers for survival in 
OTSCC   
(Makinen et al. 2015)  TLR-2, -4, and -9 73 cases TLR-2, -4, and -9 are important prognosticators in early 
OTSCC 
 
(Kelner et al. 2015) Activin A 110 cases Activin A is a prognosticator of occult lymph node 
metastasis and overall survival (OS) in early OTSCC 
(Han et al. 2015) E-cadherin and 
vimentin 
95 cases Expression of EMT (positive vimentin and negative E-
cadherin) is an indicator for cancer recurrence and nodal 
metastasis in OTSCC 
(Vered et al. 2015) Caveolin-1 64 cases Caveolin-1 in OTSCC predicts recurrence and overall 
survival 
 
(Imayama et al. 2015) FOXC2 61 cases FOXC2 is a predictor of survival in OTSCC  
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Cancer-associated fibroblasts (CAFs)  
Tumor stroma is thought to play critical roles in cancer progression. Cancer-associated fibroblasts 
(CAFs) with a myofibroblast-like phenotype represent one of the most abundant types of stromal 
cells in many cancers (Augsten 2014). An early evaluation of the presence of myofibroblasts in oral 
cancer was carried out by Kellermann et al. (Kellermann et al. 2007) who have used 
immunohistochemical analysis of α-SMA in 83 cases of tongue SCC. They found that a high 
frequency of myofibroblasts correlates with lymph node metastasis, extra-capsular spread, and poor 
overall survival. Furthermore, similar findings were reported by different studies showing that 
CAFs are predictors of cervical lymph node metastasis (Ding et al. 2014), locoregional recurrence 
(Dayan et al. 2012), disease specific survival (Bello et al. 2011), and overall survival (Dayan et al. 
2012; Ding et al. 2014) in OTSCC. In addition, Ding et al (Ding et al. 2014) found a significant 
correlation between expression of α-SMA with that of N-cadherin, vimentin, and lymphatic vessel 
endothelial hyaluronan receptor 1 (LYVE-1). They suggested that α-SMA-positive myofibroblasts 
may be associated with EMT and with the microenvironment of nodal metastasis. Moreover, a 
similarity in the pattern of CAF distribution in primary OTSCC and in metastases in regional lymph 
nodes has been reported (Vered et al. 2010). 
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3 Aims of the study 
The aims of this study were to identify powerful and easily applicable prognosticators for early 
stage (cT1-2N0) OTSCC. Specifically, the purposes of this study were: 
A. To evaluate the prognostic value of a histologic risk model, tumor budding, and depth of 
invasion in early (cT1-2N0) OTSCC (Study I).  
B. To test the predictive value of CAFs in a cohort of early (cT1-2N0) OTSCC (Study I). 
C. To evaluate the impact of several clinicopathologic factors in a large international cohort of 
early OTSCC cases from three geographic regions (Study II).  
D. To summarize the findings related to tumor budding in head and neck cancer (Study III). 
E. To introduce a simple histopathologic prognostic model for early stage OTSCC (Study IV).  
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4 Material and methods 
A total of 479 cases of early OTSCC were included (variants of SCC were not included) in this 
thesis. Of these, 233 Finnish cases were included in study I, 479 cases (224 Finnish, 109 Brazilian, 
146 American) in study II, and 311 cases (224 Finnish, 87 Brazilian) in study IV (Table 5 and 6). A 
description of the method of evaluation of each prognostic factor is provided below. 
Table 5: Clinicopathologic characteristics of patients (modified from Study I, II, and IV). 
Characteristics Number of cases (%) 
 Study I (233 cases) Study II (479 cases) Study IV (311 cases) 
Age    
 ≤ 60 years   86 (36.9) 229 (47.8) 129 (41.5) 
 > 60 years 147 (63.1) 250 (52.2) 182 (58.5) 
Gender    
 Male 109 (46.8) 262 (54.7) 165 (53.1) 
 Female 124 (53.2) 217 (45.3) 146 (46.9) 
Clinical stage    
 cT1N0 113 (48.5) 212 (44.3) 124 (39.9) 
 cT2N0  120 (51.5) 267 (55.7)  187 (60.1)  
Tumor grade    
 I (well differentiated)   83 (35.6) 129 (26.9) 105 (33.8) 
 II (moderately differentiated) 109 (46.8) 258 (53.9) 131 (42.1) 
 III (poorly differentiated)   41 (17.6)   92 (19.2)    75 (24.1) 
Worst pattern of invasion    
 Cohesive   53 (22.7) 166 (34.7)   78 (25.1) 
 Invasive (infiltrative) 180 (77.3) 313 (65.3)  233 (74.9) 
Lymphocytic hostresponse    
 Strong or intermediate 120 (61.2) 246 (51.4) 169 (54.3) 
 Little or no response   76 (38.8) 233 (48.6)  142 (45.7) 
Perineural invasion    
 Absent 198 (85.0) 376 (78.5) 269 (86.5) 
 Present   35 (15.0) 103 (21.5)    42 (13.5) 
Histologic risk score    
 Low risk (< 3) 111 (47.6) 192 (40.1) 130 (41.8) 
 High risk (≥ 3) 122 (52.4) 287 (59.9) 181 (58.2) 
Tumor budding    
 Low (< 5 buds)  152 (65.2) - 215 (69.1) 
 High (≥ 5 buds)    81 (34.8) -   96 (30.9) 
Depth of invasion    
 Superficial (< 4 mm)    80 (34.3) 151 (31.5) 116 (37.3) 
 Deep (≥ 4 mm)  153 (65.7) 321 (67.0) 195 (62.7) 
 Missing     -     7 (1.5) - 
BD model    
 Low risk (0) - - 103 (33.1) 
 Intermediate risk (1) - - 125 (40.2) 
 High risk (2) - -   83 (26.7) 
Cancer associated fibroblast*    
 Low score (0-1)  27 (32.9) - - 
 Medium score  (2-3)  40 (48.8) - - 
 High score (4)  15 (18.3) - - 
* Only samples of 82 patients were available for staining. 
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Table 6: Clinicopathologic characteristics of 479 patients who have been involved in the analysis of disease-specific 
survival (DSS) and disease-free survival (DFS). Modified from Study I, II, and IV. 
Characteristic 
 
Number of cases (%) 
 Finland*  
n=224 (%)  
USA 
n=146 (%)  
Brazil  
n=109 (%) 
Total 
n=479 (%) 
Age (years)     
  10-40 17 (7.6) 13 (8.9) 12 (11.0)   42 (8.8)  
  41-59 63 (28.1) 65 (44.5) 48 (44.0) 176 (36.7) 
  60-74 85 (37.9) 52 (35.6) 37 (33.9) 174 (36.3) 
  75-96 59 (26.3) 16 (11.0) 12 (11.0)   87 (18.2) 
Gender     
  Male  105 (46.9) 81 (55.5) 76 (69.7) 262 (54.7) 
  Female 119 (53.1) 65 (44.5) 33 (30.3) 217 (45.3) 
Grade     
  I (well differentiated)   81 (36.1)   17 (11.6) 31 (28.4) 129 (26.9) 
  II (moderately differentiated) 103 (46.0) 114 (78.1) 41 (37.6) 258 (53.9) 
  III (poorly differentiated)    40 (17.9)   15 (10.3) 37 (33.9)   92 (19.2) 
Clinical stage     
  T1N0 108 (48.2) 86 (58.9) 18 (16.5) 212 (44.3) 
  T2N0 116 (51.8) 60 (41.1) 91 (83.5) 267 (55.7) 
WPOI      
 Low 52 (23.2) 74 (50.7) 40 (36.7) 166 (34.7) 
 High 172 (76.8) 72 (49.3) 69 (63.3) 313 (65.3) 
LHR     
 Strong or intermediate 144 (64.3) 59 (40.4) 43 (39.4) 246 (51.4) 
 A little or no response   80 (35.7) 87 (59.6) 66 (60.6) 233 (48.6) 
PNI     
 Absent 189 (84.4) 89 (61.0) 98 (89.9) 376 (78.5) 
 Present    35 (15.6) 57 (39.0) 11 (10.1) 103 (21.5) 
Histologic risk score     
 Low risk (< 3) 108 (48.2)   45 (30.8) 39 (35.8) 192 (40.1) 
 High risk (≥ 3) 116 (51.8) 101 (69.2) 70 (64.2) 287 (59.9) 
Depth of invasion     
 < 4mm   79 (35.3)   31 (21.2) 41 (37.6) 151 (31.5) 
 ≥ 4mm 145 (64.7) 115 (78.8) 61 (56.0) 321 (67.0) 
 Missing          -        -   7 (6.4)     7 (1.5) 
* Nine cases were excluded due to insufficient data on recurrence. 
4.1 Evaluation of cancer associated fibroblasts (Study I) 
Paraffin embedded blocks of 82 cases treated for early stage (cT1N0, n = 31; and cT2N0, n = 51) 
OTSCC were retrieved from the archives of three Finnish University hospitals located in Helsinki 
(n = 18), Oulu (n = 37), and Kuopio (n = 27). The immunohistochemical staining of α-smooth 
muscle actin (α-SMA) was carried out on sections of 4 µm thickness which were first 
deparaffinized in xylene and rehydrated through a series of graded ethanols. For antigen retrieval, 
the sections were heated (10 minutes) in a microwave oven (10mmol/L citrate buffer, pH 6.0). Then 
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endogenous peroxidase quenched in 0.3% hydrogen peroxide (diluted in H2O). The sections were 
incubated at room temperature for 60 minutes with the primary antibody: monoclonal mouse anti-α 
SMA (diluted 1:1000) manufactured by Dako A/S, Glostrup, Denmark. After that, the slides were 
overlaid with a biotinylated secondary antibody, and a Histostain SP kit (Zymed, San Francisco, 
CA, USA) was used for antibody detection. Color was developed in diaminobenzidine solution 
(DAKO A/S Denmark). Counterstaining was done with Mayer’s hematoxylin and the slides were 
rehydrated and mounted. Between the staining steps, the sections were washed with phosphate 
buffered saline (PBS). 
Each case was scored according to the area with the densest staining. The slides were first scanned 
with low magnification (×4 objective), and then the density of CAFs was assessed using a ×10 
objective (2.6 mm square). The density of cancer-associated fibroblasts (CAFs) was used to classify 
the cases into 2 groups: High CAF score (or CAF rich pattern) vs. low CAF score (or CAF poor 
pattern). The cases were also categorized into 3 groups (low, intermediate, and high) to compare 
with a previous study (Bello et al. 2011).  
4.2 Evaluation of tumor budding, depth of invasion and histologic risk score in 
early stage OTSCC (Study I)  
The hematoxylin and eosin (H-E) stained surgical slides of 233 cases treated for early stage (cT1-
2N0) OTSCC at the five Finnish University hospitals (Helsinki, Turku, Tampere, Oulu and Kuopio) 
were retrieved. The patients’ clinicopathological characteristics are shown in Table 5. Tumor 
budding (TB) and depth of invasion (DOI) were scored as explained previously in other studies 
(Jerjes et al. 2010; Wang et al. 2011). In brief, TB is defined as the presence of single cancer cells 
or small clusters of less than five cells at the invasive front (IF) of the tumor (Fig. 4). The IF of all 
available sections was scanned using a low magnification (×4) objective, then the field with the 
highest tumor budding was counted using a high magnification objective (×20). For risk 
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stratification based on TB, a cutoff of five buds (low risk <5 buds vs. high risk ≥5 buds) was used. 
DOI was measured from the tumor surface to the point of deepest invasion. A cutoff point of 4 mm 
was used to classify cases based on DOI (superficial <4mm vs. deep ≥4mm), as recommended in a 
recent meta-analysis (Huang et al. 2009). The parameters of the histologic risk score (HRS), which 
include worst pattern of invasion (WPOI), lymphocytic host response (LHR), and perineural 
invasion (PNI), were scored as previously described (Brandwein-Gensler et al. 2005) and explained 
briefly in Table 3.  
4.3 Evaluation of prognostic impact of age in early OTSCC (Study II) 
To recruit a large number of young cases, we conducted a collaboration with Dr. Simion I. Chiosea 
and Dr. Ann Margaret Chang (Department of Pathology, University of Pittsburgh Medical Center, 
Pittsburgh, PA). The data of 146 cases treated there for early (cT1-2N0) OTSCC were retrieved and 
included in this study. In addition, the data of 109 cases treated at the A.C. Camargo Hospital, Sao 
Paulo, Brazil were also included in this analysis forming a total of 479 cases with early stage 
OTSCC as a cohort for this study (Table 6). To analyze the impact of age on the prognosis of early 
OTSCC, patients were grouped into 4 age groups (≤40 years, 41-59 years, 60-74 years, and 75-96 
years).  
4.4 Validation of prognostic value of DOI and WPOI in a larger patient cohort 
from three geographic regions (study II)  
The data of 479 cases (Table 6) involved in the age analysis were also used to validate our previous 
findings about DOI and WPOI reported in study I.  The scoring of histopathologic parameters of the 
cases from Brazil and the USA was performed using the same criteria as in study I. Data on tumor 
depth were missing in 7 cases from Brazil (1.5%).  
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4.5 Systematic review of studies of tumor budding in HNSCC (study III) 
The search word tumo(u)r budding (both English and American spelling) was employed for the 
databases of Scopus, PubMed and Web of Science. Our search was limited to literature in the 
English language only, up to and including February 2014. Later on, the search was updated to 
include literature up to and including March 2015 (Fig. 5). The search results were then refined 
using the following terms: head and neck squamous cell carcinoma, oral squamous cell carcinoma, 
oral tongue squamous cell carcinoma, tongue squamous cell carcinoma, nasopharyngeal carcinoma, 
laryngeal squamous cell carcinoma, oropharyngeal squamous cell carcinoma, hypopharyngeal 
squamous cell carcinoma and sinonasal squamous cell carcinoma.  
 
Figure 5: Flowchart of database searches (study III and unpublished data). 
4.6 Proposal for new prognostic model in early OTSCC (study IV) 
The H-E stained surgical slides of 87 cases treated for early stage (cT1-2N0) OTSCC at the A.C. 
Camargo Hospital, Sao Paulo, Brazil were retrieved and scored for the presence of TB and 
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measured for DOI. From the Finnish cohort involved in study I, 9 cases were excluded due to 
insufficient data for recurrences. Thus a total of 311 cases were eligible for study IV, which 
comprised the rest of the Finnish cases (224 cases) and the 87 Brazilian cases (Table 5). The cut off 
points for risk stratification of both tumor budding and depth of invasion were similar to those used 
in study I. The scores of tumor budding and depth of invasion were assigned in one predictive 
model (BD model) as follows:   
Score 0: Both tumor budding and depth of invasion are less than the cut-off points.  
Score 1: Either tumor budding or depth of invasion exceeds the cut-off point.  
Score 2: Both tumor budding and depth of invasion exceed the cut-off points. 
4.7 Statistical analysis 
Statistical analyses were carried out using SPSS software. The impact of the studied factors on 
prognosis of early OTSCC patients was evaluated in relation to disease-specific survival (study I, II 
and IV), disease-free survival (study II and IV), and overall survival (study II). Disease-free 
survival (DFS) was defined as the time from surgery to recurrence (at the site of the primary tumor, 
in neck LNs, or both) or the last date of follow-up. Kaplan-Meier (KM) plots were constructed to 
present cumulative survival outcomes and compared using a log rank test. Similarly KM plots were 
constructed for DFS using recurrence as the end point. The unadjusted (univariate) analysis was 
used for single parameters. The adjusted (multivariate) analysis was fitted with categorical 
covariates to assess the strength of each parameter.  
4.8 Ethics statement  
Use of patient materials and follow-up information were approved by the following authorities: The 
National Supervisory Authority for Welfare and Health “VALVIRA” (for study I, II, and IV), the 
Brazilian Human Research Ethics Committee (for study II and IV), and the Total Quality Council of 
the University of Pittsburgh Medical Center (for study II).  
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5 Results 
The clinicopathologic characteristics of the patients were explained in Table 5 and Table 6.	   There 
was significant variation (Pearson Chi-Square, P < 0.05) among the cohorts as follows: In the 
Finnish cohort, there were more old patients (≥ 75 years), more women, and more invasive tumors 
than in the Brazilian or the US cohorts. The tumors in the Brazilian patients were more poorly 
differentiated and larger than those in the Finnish or US patients. In the US patients, there were 
more PNI, and the number of deeper tumors (≥ 4mm) was more than in the Finnish or Brazilian 
cohorts.  
5.1 Cancer associated fibroblasts in early stage OTSCC (study I)  
According to the density of CAFs, 27 cases (32.9%) were assigned a low score, 40 cases (48.8%) 
received a medium score, and 15 cases (18.3%) had a high score. The density of CAFs showed a 
weak correlation with cancer mortality, and was not a promising predictor of survival when cases 
were stratified into low and high risk groups based on the density of CAFs (P = 0.4). The 
cumulative survival curves (Fig. 6) showed that the CAF rich pattern was not associated with a 
higher rate of OTSCC mortality when compared to CAF poor pattern (i.e. low and intermediate 
scores together). 
 
Figure 6: Disease-specific survival of OTSCC patients in 
relation to density of CAFs. 
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5.2 Tumor budding in early stage OTSCC (study I) 
One hundred and fifty two cases (65.2%) had a low budding score (<5 buds), while 81 cases 
(34.8%) had a high score (≥5 buds). High scores of TB were significantly associated with a higher 
rate of OTSCC mortality with a HR of 2.04 (95% CI 1.17–3.55), P = 0.01. 
5.3 Histologic risk score (HRS) in early stage OTSCC (study I and II)  
HRS was evaluated in 233 cases of early stage OTSCC (Table 5), and did not show any association 
with patient survival (P > 0.05). Furthermore, we have evaluated separately the prognostic impact 
of each parameter involved in the HRS (WPOI, LHR, and PNI). Only WPOI was associated 
strongly with mortality due to OTSCC (HR 4.47; 95% CI 1.59–12.51; P = 0.004). Moreover, we re-
evaluated the prognostic role of HRS and its parameters (WPOI, LHR, PNI) in a larger cohort 
(study II) of 479 cases (Table 5). Similarly, HRS did not show a predictive role for survival 
(unpublished data). In particular, the WPOI turned out to be a prognostic feature for OTSCC 
mortality (HR 2.34; 95 CI 1.26-4.32). However, the WPOI was not a strong predictor for 
locoregional recurrence in early OTSCC (HR 1.46; 95% CI 0.95-2.25). 
5.4 Depth of invasion (DOI) in early stage OTSCC (study I, II)  
In the Finnish cohort (study I), DOI showed a strong predictive power for DSS in early OTSCC 
(HR 2.55; 95% CI 1.25-5.20, P = 0.01). The same result was confirmed in our multicenter study 
from Finland, Brazil, and the USA (study II) which reported DOI as a prognosticator for DSS (HR 
2.44; 95% CI 1.34-4.47), and also for DFS, but with less predictive power for the latter (HR 1.67; 
95 CI 1.07-2.60). 
5.5 Impact of age on the prognosis of early OTSCC (II) 
Forty two patients (8.8%) were ≤ 40 years of age, 176 patients (36.7%) were between 41 to 59, 174 
patients (36.3%) were between 60 to 74, and 87 patients (18.2%) were 75 years old or older. 
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Statistical analysis did not show any evidence for poor prognosis in young patients with early 
OTSCC. At the same time, the analysis did not allow a definitive result concerning the prognosis of 
young patients with OTSCC due to the small number of recurrences and cancer-related mortality in 
this young group. Instead, old patients (≥ 75 years) were shown to have a higher rate of 
locoregional recurrence (HR 1.74; 95% CI 1.08-2.81), and a higher incidence of cancer mortality 
(HR 2.39; 95% CI 1.30-4.40). 
5.6 Tumor budding (TB) in HNSCC (study III)    
The result of database searches until March 2014 retrieved 122 hits, and TB has been evaluated in 
only five of them (study III). In addition, an update of the database searches revealed another five 
studies, which have examined TB (not included in our systematic review published earlier). In total, 
10 studies (Table 7) examined TB in HNSCC as follows: three studies (Angadi et al. 2015; 
Marangon Junior et al. 2014; Sawazaki-Calone et al. 2015) in OSCC (different subsites), two in 
TSCC (Wang et al. 2011; Xie et al. 2014), two in early OTSCC (Almangush et al. 2014; 
Almangush et al. 2015), one study in the gingival-buccal complex SCC (Manjula et al. 2015), one 
in laryngeal SCC (Sarioglu et al. 2010) and one in nasopharyngeal carcinoma (Luo et al. 2012). 
Two studies from our group (Almangush et al. 2015; Sawazaki-Calone et al. 2015) have analyzed 
TB as a part of the BD predictive model (study IV). Interestingly, the findings of these ten studies 
indicate that TB has a prominent role in progression and prognosis of HNSCC. Table 7 summarizes 
these studies.  
 
 
 
 
 
 
	  39 
	  
Table 7: Summary of 10 studies that examined TB in HNSCC. 
Author and year Site Stage Cases Cutoff/Stain Main findings 
(Sarioglu et al. 2010) Larynx II–IV 64 2/3 of IFa/H-Eb TB is a prognosticator for distant 
metastasis in laryngeal SCC, P = 0.04 
(Wang et al. 2011) Tongue I–IV 133 5 budsc/H-E TB is a predictor of overall survival, HR 
3.02 (95% CI 1.53-5.97), P = 0.001. TB 
has a strong association with EMT 
(Luo et al. 2012) Nasopharynx I–IV  105 5 buds/IHCd TB is a predictor of survival, HR 4.17 
(95% CI 1.85-9.37), P = 0.001. Budding 
cells have a higher level  of ALDH1, P < 
0.001 
(Almangush et al. 
2014) 
Oral tongue I-II 233 5 buds/H-E TB is a predictor of DSS, HR 2.04 (95% 
CI 1.17-3.55), P = 0.01 
(Marangon Junior et 
al. 2014) 
Oral cavity NA 57 5 buds/IHC High scores of TB associated with high 
density of stromal myofibroblasts, odds 
ratio (OR) 6.18 (95 CI 1.49-25.57), P < 
0.05. High TB associated with high 
expression of laminin-5 gamma2, OR 
16.04 (95% CI 3.61-71.19), P < 0.05 
 
Update of database searches  
(Xie et al. 2014) Tongue I-II 195 5 buds/IHC TB is a predictor of survival in early 
TSCC, HR 5.58 (95%CI 1.22-25.38), P = 
0.02 
(Angadi et al. 2015) Oral Cavity I-IV 75 10 budse/H-E High-TB score is a predictive marker for 
lymph node metastasis, OR 6.79 (95% 
CI 2.28-20.18), P = 0.001 
(Manjula et al. 2015) Gingivo-
buccal 
complex 
I-IV  33 10 budsf/H-E TB is a predictor of nodal metastases 
(only in univariate analysis), P = 0.014 
(Almangush et al. 
2015) 
Oral tongue I-II 311 5 buds/H-E TB is a parameter of the BD prognostic 
model (study IV). TB was a predictor of 
DSS, HR 1.76 (95% CI 1.01–3.06), P = 
0.044; and also a predictor of recurrence, 
HR 1.80 (95% CI 1.10–2.93), P = 0.020 
(Sawazaki-Calone et 
al. 2015) 
Oral cavity I-IV 113 5 buds/H-E TB is a parameter of the BD prognostic 
model which is introduced in study IV 
a:  High score = budding is present in ≥ 2/3 of the IF area 
b: Hematoxylin and eosin 
c: Low <5 buds; High ≥5 buds 
d: Immunohistochemistry (pan-cytokeratin staining) 
e: Low: <10 buds; High: ≥10 buds 
f: Low: ≤10 buds; High >10 buds 
NA: Not available 
 
5.7 A histopathologic prognostic model (BD model) for early stage OTSCC (IV) 
According to BD scores (0-2), 103 cases (33.1%) had score 0 (low risk), 125 cases (40.2%) had 
score 1 (intermediate risk), and 83 cases (26.7%) had score 2 (high risk). A high BD score (score 2) 
predicted the locoregional recurrence (HR 2.19, 95% CI 1.20-4.00) as shown in Figure 7A. 
Similarly, score 2 predicted the cancer-specific mortality (HR 5.11, 95% CI 2.05-12.75) (Fig 7B).  
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Figure 7: Disease-free survival (A) and disease-specific survival (B) in early OTSCC patients in relation to BD scores. 
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6 Discussion 
At an early stage (cT1-2N0), OTSCCs are characterized by a high incidence of recurrences, occult 
metastases and cancer-related mortality. This indicates that the risk of poor prognosis has been 
underestimated by the current cTNM staging, and this subsequently leads to inappropriate 
management. Numerous previous studies have proposed new prognostic factors for OTSCC. Most 
of these studies have shown important methodological shortcomings including heterogeneity of 
tumor site (i.e. including cancers of all oral cavity subsites), heterogeneity of tumor stage (i.e. 
including early and late stages), a time-consuming or labor-intensive protocol due to special 
methodology (e.g. immunostaining requirements), complexity of suggested scoring methods in 
some systems, conclusions based on very small cohorts, or the experience of a single institution 
only. In this study, we have attempted to overcome such obstacles by introducing prognosticators 
that could easily be included in pathology reports and would be applicable for survival assessment 
in early OTSCC. Since there were differences in the percentages (%) of the studied parameters 
between the cohorts, we have included the centers as a variable in the multivariate analysis of the 
Finnish study. In addition, the countries were categorized as a variable in the multivariate statistical 
analysis of the international cohorts. There was no significant difference between the centers or the 
countries on multivariate analysis. Below, we provide a brief discussion on each prognostic factor 
examined in this study. 
6.1 Cancer associated fibroblasts (CAFs) in early OTSCC  
The tumor microenvironment makes a strong contribution to cancer progression, and α-SMA 
positive myofibroblasts are among the main components of this microenvironment (Thode et al. 
2011). Prior research from our group (Bello et al. 2011) and others (Ding et al. 2014; Kellermann et 
al. 2007) has demonstrated that the density of CAFs is an independent predictor in OTSCC. 
Notably, most of the previous studies have included early and late stages of OTSCC. According to 
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the best of our knowledge, no previous study has evaluated CAFs in a homogenous cohort of early 
OTSCC or early OSCC. However, we found that CAFs have little or no prognostic value in early 
OTSCC. Similarly, a recent study analyzed CAFs in early OTSCC, and demonstrated that their 
prognostic value does not have statistical significance (Kelner et al. 2015). Interestingly, a high 
CAF score was an unusual event in our cohort. We speculated that an increase in density of CAFs 
in OTSCC might require more time than is available during the early stages. However, larger 
cohorts than ours are required to reach conclusions on the role of CAFs in early OTSCC.  
6.2 Tumor budding (TB) in early OTSCC 
TB has been identified as a histopathologic prognostic marker in various cancers (Karamitopoulou 
et al. 2013; Landau et al. 2014; Lugli, Karamitopoulou and Zlobec 2012). The current study is the 
first to examine the prognostic power of TB in early OTSCC. Interestingly, a recent study on early 
tongue cancer has found that a high intensity of TB is a predictor of poor survival. In addition, they 
found that TB is a prognosticator for occult metastases (Xie et al. 2014). TB has been suggested as 
analogous to epithelial cells that are undergoing EMT in tongue cancer (Wang et al. 2011), and 
correlate strongly with EMT in other cancers (Karamitopoulou 2012; Niwa et al. 2014). It was 
demonstrated that reduced expression of a cell adhesion molecule (E-cadherin) occurs in the 
budding cells of tongue cancer (Wang et al. 2011) and other cancers (Nakagawa et al. 2013; 
Yamaguchi et al. 2010). Moreover, a recent genetic study has compared cells from a center of 
OSCC with budding cells and found that the latter have a particular gene expression signature 
including factors involved in EMT (Jensen et al. 2015a). This study also noted many genes that 
indicate an increase in production of extracellular matrix in budding cells.  
High TB scores were strongly correlated with increased density of stromal myofibroblasts in OSCC 
(Marangon Junior et al. 2014). However, Jensen et al. (Jensen et al. 2015b) in their in vivo study 
have reported that the presence of TB is not dependent on the existence of stromal myofibroblasts. 
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Therefore, the crosstalk between the invading TB cells and myofibroblasts still requires further 
research.  
In cancers other than OSCC, there is more research on TB, and several markers related to cancer 
progression have correlated strongly with TB. For example, a cancer stem cell marker, aldehyde 
dehydrogenase 1, was associated with TB in nasopharyngeal carcinoma (Luo et al. 2012). In 
colorectal cancer, TB was associated with cathepsin B (Guzinska-Ustymowicz 2006) and the 
epidermal growth factor receptor (EGFR) (Ljuslinder et al. 2011). 
Our systematic review has demonstrated TB as a promising prognostic marker in HNSCC. TB has 
been studied in patient cohorts of OSCC, gingival-buccal SCC, tongue SCC (all stages), early 
OTSCC, LSCC and NPC (Table 7). In these studies, tumors were associated with different 
etiological factors. Moreover, the method of TB assessment was not similar in some studies, and the 
cutoff point for risk stratification varied. In addition, variation in the size of the field among the 
optical microscopes is also expected (i.e. square mm area of ×20 objective varies from one 
microscope to another). In our cohort, we have used an OLYMPUS BH2 which has ×20 objective 
of 1.3 mm square.   
6.3 Depth of invasion (DOI) in early OTSCC 
Evaluation of DOI in our cohort of 479 cases (study II) with early OTSCC has revealed that DOI is 
a significant predictor for both LRR and DSS. The results of various studies have shown 
disagreement on the optimal cutoff point for risk stratification (Ganly, Patel and Shah 2012; Han et 
al. 2015; Huang et al. 2009). Such disagreement is one of the main obstacles for using DOI as a 
guide in management of early OTSCC. However, inclusion of SCC from different subsites of the 
oral cavity in the same analysis is possibly one of the reasons for the disagreement between 
previous publications. There is evidence that DOI ≥ 2 mm is high risk for cases having a SCC in the 
floor of the mouth while in tongue SCC, DOI ≥ 4 mm cases were at high risk (Balasubramanian et 
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al. 2014). Notably, DOI has been suggested as a modification for current cTNM staging in OSCC 
(Ebrahimi et al. 2014; Hubert Low et al. 2015; Piazza et al. 2014a). However, further research is 
needed to confirm the usefulness of such a modification. 
6.4 Histologic risk score (HRS) in early OTSCC  
HRS was introduced in 2005 by Brandwein-Gensler and colleagues (Brandwein-Gensler et al. 
2005). This prognostic model is based on three histopathologic parameters: WPOI, LHR and PNI. 
Her group has validated this model twice: First in 2010 (Brandwein-Gensler et al. 2010), and later 
in 2013 (Li et al. 2013) using a cohort of early OSCC only. However, our current study did not find 
significant prognostic power for HRS in early OTSCC. To avoid potential bias in scoring of HRS, 
we have analyzed the prognostic value of HRS separately in 146 cases of early OTSCC scored by 
Chang et al. (Chang et al. 2013), but also then we did not find significant predictive value for HRS 
(unpublished data). Similarly, in their recent study Rodrigues and colleagues did not find prognostic 
power for HRS in a large cohort of 202 cases of OTSCC (all stages). (Rodrigues et al. 2014). 
According to our experience with HRS, we noted that the model will assign a high risk score (score 
3) in cases with little or no host response (Table 3). We argue that in such cases the cancer may 
show cohesive invasion (i.e. pushing border, finger-like growth or large separate islands) and also 
no PNI. Similarly for WPOI or PNI, tumor cases will be assigned score 3 (high risk) if only one of 
these parameters is high irrespective of the other parameters. Therefore, several cases have been 
assigned high risk (score 3) when they only had one parameter with a high score. Thus, in HRS the 
assignment of high risk (score 3) can be based on a single parameter instead of a combined score.  
Our separate analysis of each of the parameters included in the HRS has shown that only WPOI is 
an independent prognosticator in early OTSCC. This is also in line with findings from other studies 
(Li et al. 2013; Yanamoto et al. 2013). It is speculated that anti-tumor effects of the inflammatory 
cells might play a role in prognostication of patient survival. For example, a high density of 
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inflammatory infiltration was associated with a favorable survival in OTSCC (Chatzistamou et al. 
2010) and TSCC (Lundqvist et al. 2012). However, the analysis of LHR in our cohort did not show 
any predictive power in early OTSCC. A shortcoming should be acknowledged; in this study LHR 
was analyzed as a single parameter (on hematoxylin and eosin stained slides) without identifying 
the different subtypes of lymphocytes. 
6.5 Tumor grade (differentiation) in early OTSCC 
Our data analysis has shown a weak prognostic power of tumor grade in early OTSCC. On the other 
hand, Thomas et al. (Thomas, Stedman and Davies 2014) recently analyzed the database of 
Surveillance, Epidemiology, and End Results (SEER), and reported a strong correlation between 
poorly differentiated tumors and mortality in early OSCC (in all subsites of the oral cavity). 
However, Ganly et al. (Ganly et al. 2013) did not find tumor grade to have significant prognostic 
value for recurrence (local or regional) in a series of 164 cases treated for early OTSCC. The same 
finding is presented in our current study, which has the largest series of early OTSCCs to date. The 
current data have enough statistical power to address this issue and to conclude that tumor grade is 
not a promising prognosticator in early OTSCC. 
6.6 Prognostic impact of patient age in early OTSCC 
The current study has conducted an international collaboration of seven institutions but the number 
of young patients (≤ 40 years) is still small (42 cases). However, in this material we did not find 
evidence for poor survival in young patients compared to other age groups. Conversely, we have 
noted that the risk of recurrence and cancer-specific mortality increases with age, and is distinctly 
more common in the oldest age group (≥ 75 years). Based on our results we are not able to say 
whether young patients have a worse, better or similar survival, because the number of recurrences 
and deaths among the young were very small. Notably, Knopf and colleagues (Knopf et al. 2015) 
has compared the outcome of 66 young patients (≤45 years) with 210 older ones, and found that 
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young patients have a significantly better survival. However, Manuel et al. (Manuel et al. 2003) 
have reported that the prognosis is similar in OTSCC patients younger or older than 45 years. 
Importantly, our data analysis and review of the literature indicate that caution should be exercised 
in inferring poor prognosis in the young age group with OTSCC. Limitations in previous studies 
such as small numbers of young patients and/or small numbers of survival events (Garavello, 
Spreafico and Gaini 2007; Soudry et al. 2010; Vargas et al. 2000) could have influenced their 
results.  Such limitations also hamper definitive conclusions about the impact of young age on the 
prognosis of OTSCC. Of note, studies which have analyzed population-based registries, have not 
reported poor prognosis in young age groups. Conversely, some of these population studies have 
reported a better prognosis in young patients. For example, Annertz et al. (Annertz et al. 2002) have 
analyzed data from cancer registries in Scandinavian countries (Denmark, Finland, Norway and 
Sweden), and reported a total of 5,024 patients with tongue SCC between 1960 and 1994. Of these, 
276 patients (5.5%) belonged to the young age group (< 40 years). Interestingly, their study 
reported a significantly better survival for young patients compared to older ones.  
In our data, two pediatric cases (< 20 years) were treated for early OTSCC. These two cases had 
recurrences and both patients died of OTSCC. However, data on survival of OTSCC in children are 
still insufficient because it is a very rare clinical entity.  
6.7 A proposal for a new histopathologic predictive model in early OTSCC 
The main result of this study is the BD predictive model (Fig. 8 and 9), which has the advantages of 
being simple, easily applicable, and requiring inexpensive staining. The two parameters (Budding 
and Depth) included in this model have been reported earlier as promising prognosticators in tongue 
SCC (Ganly et al. 2013; Wang et al. 2011; Xie et al. 2014), as well as in SCCs of other oral subsites 
(Angadi et al. 2015; Huang et al. 2009).  
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Initial reports of several prognosticators of OTSCC indicated they had excellent predictive power, 
but subsequent studies have failed to validate them. In general, new prognosticators of malignancies 
should be better than the ones already available (Soland and Brusevold 2013). Based on this 
recommendation, we have (Sawazaki-Calone et al. 2015) compared the prognostic performance of 
our BD model with that of the WHO grading system of SCC (Barnes et al. 2005), a malignancy 
grading system of the deep invasive front (Bryne et al. 1992), and the histologic risk score (HRS) 
model (Brandwein-Gensler et al. 2005) in a new cohort of 113 OSCC patients from Brazil. To avoid 
possible bias and to evaluate the reproducibility of our model, other observers have performed the 
scoring of this new cohort of OSCC following the same criteria we have previously introduced for 
the BD model. The findings of this validation study demonstrated that the BD model has a 
promising prognostic power superior to that of other examined models. However, the validation 
study has the disadvantages of including SCC of more than one oral cavity subsite, and also 
including cancers of both early and late stages. Therefore, further validation of the BD model 
preferably should be carried out using a homogenous patient cohort similar to that of the current 
study. Moreover, further studies should compare the different method of scoring of TB similar to 
that recently conducted on colorectal cancer (Koelzer et al. 2015). Comparing different cutoff 
points for risk stratification based on TB and DOI could help identification of the ideal cutoff points 
for the components of this model. 
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Figure 8: Histopathology of BD model. A: score 0; B: score 1; C: score 2. D, E, and F: magnification of 
rectangular boxes of A, B and C respectively. 
 
 
 
 
Figure 9: Schematic illustration of BD model. A: score 0; B and C: score 1; D: score 2. 
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7 Conclusion 
In this multicenter international study we have examined many clinicopathologic parameters that 
have been suggested to play a role in prognostication of oral cancers. Specifically: 
A. We introduced a novel prognostic model (BD model) for the prediction of patient survival. 
Our model is based on simple histopathologic parameters, which could be easily evaluated 
during the operation and allow the surgeon to decide the definitive surgical procedure (i.e. 
wider surgical margins and SNB or neck dissection) for cases at high risk without 
interrupting anesthesia. In addition, this model will be useful to select those patients who 
might need postoperative radiotherapy. 
B. We evaluated the prognostic power and the significance of many histopathologic parameters 
in one of the largest patient cohorts of early OTSCC. The examined parameters are usually 
evaluated by pathologists in daily practice and included in the pathology reports. Only depth 
of invasion and pattern of invasion (defined as WPOI) have shown a promising predictive 
value. However, tumor grade has a weak predictive power; while perineural invasion and 
lymphocytic host response did not show any predictive power. 
C. We found that the histologic risk model is not a promising prognostic indicator in early 
OTSCC. 
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